Ketamine

Ketamine is a prescription dissociative anesthetic. Clinicians use it to start and maintain general anesthesia, and hospitals reach for it during short procedures and for acute pain. At much lower doses, clinics and telehealth programs use it off label for depression and some chronic pain problems. It is a controlled substance. It is not a supplement, and it is never sold over the counter.

What ketamine is, and what type of drug it is

The word dissociative describes the experience. The medicine can make your body, your surroundings and your sense of time feel separated from you. People often describe floating, or watching themselves from a short distance away. That effect is part of how the drug works, not an accident, although it can feel alarming if nobody explains it beforehand.

The product with full United States labeling is Ketalar, an injection of ketamine hydrochloride given into a vein or a muscle. Its label lists three jobs: use as the sole anesthetic for diagnostic and surgical procedures that do not need muscle relaxation, induction of anesthesia before other anesthetic agents, and use as a supplement to other anesthetics. The approval history and current labeling are searchable through the FDA drug approvals database.

The Drug Enforcement Administration classifies it as a Schedule III controlled substance. That classification means two things at once: accepted medical use, and a genuine potential for misuse. Federal scheduling is the reason prescriptions carry extra paperwork, refill limits and stricter telemedicine rules than an antidepressant tablet does, as set out in the DEA fact sheet for this drug.

Is it an opioid?

No. Opioids such as morphine and oxycodone work mainly at opioid receptors, and naloxone reverses them. This anesthetic works chiefly by blocking NMDA receptors, which respond to a brain chemical called glutamate. It belongs to a different chemical family and behaves differently in the body. Researchers are still studying whether opioid pathways play any part in its mood effects, and that question remains open. It does not make the drug an opioid, and it does not mean an opioid overdose antidote will reverse it.

What the label approves, and where depression treatment fits

The injectable product is approved for anesthesia and sedation. In practice it is used across a wide age range, including children, because it tends to preserve breathing better than some alternatives when given carefully. Emergency departments also use it for severe pain and for procedures. A clinical summary of these uses appears in the NIH StatPearls chapter on ketamine.

Depression is a different story. When an infusion clinic or a telehealth program treats depression with this medicine, that is off-label prescribing. Off label is legal and common in medicine. It simply means the FDA has not reviewed and approved that specific use, so the safety and effectiveness data behind it were not part of the approval package. A plain summary of that gap is set out by public health researchers at Johns Hopkins.

One related product does carry approval for psychiatric use. Esketamine nasal spray, the S-enantiomer of the same molecule, is FDA approved for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. It is only given in certified healthcare settings, with monitoring after each dose, under a restricted program called a Risk Evaluation and Mitigation Strategy. The FDA explains that framework on its page on restricted drug safety programs.

What the research supports, broadly, is a fast but temporary drop in depression symptoms for some people who have not improved on standard antidepressants. Effects can appear within hours or days rather than weeks. They also fade, which is why programs talk about a series of sessions and then maintenance. Long-term data on repeated dosing over years is thinner than the short-term data. Other off-label uses, including chronic pain syndromes, PTSD and obsessive-compulsive disorder, rest on smaller studies. Our Telehealth Editorial Coverage tracks how mental health programs describe their protocols.

How it works in the brain

The short version: it interrupts one signalling system so the brain briefly ramps up another. By blocking NMDA receptors, the drug triggers a surge of glutamate, the brain’s main excitatory messenger. That surge activates a second set of receptors, called AMPA receptors, and switches on growth pathways linked to brain-derived neurotrophic factor.

Those pathways help neurons form new connections. Researchers think this rapid rebuilding of synapses, the junctions between nerve cells, explains why mood can lift long after the drug itself has cleared the body. Standard antidepressants work mostly on serotonin and norepinephrine, which is a slower route. That mechanical difference is the reason people describe the response as fast rather than gradual.

Scientists are also studying breakdown products of the drug, especially hydroxynorketamine, which produced antidepressant-like effects in animals without strong dissociation. Whether that translates to people is unsettled. What matters for a patient is simpler: the dissociative experience and the mood effect may not be the same thing, so a stronger trip does not mean a better outcome. Background on depression treatment research is maintained by the National Institute of Mental Health.

The brain effects are not all positive, either. Repeated heavy exposure has been linked to memory and attention problems in studies of people who use the drug recreationally. Supervised low-dose treatment is a different exposure pattern, but it is not risk free, and nobody should assume a clinical setting removes the question.

How it makes you feel, and the side effects to expect

During a session, most people notice the mental effects first. Common descriptions include heaviness in the limbs, distorted sight and sound, slowed or stretched time, emotional distance from difficult memories, and sometimes vivid imagery. Some people find it peaceful. Others find it frightening, especially without a calm room and a clear explanation of what is coming.

The official labeling flags a specific recovery problem called emergence reactions: confusion, agitation, vivid dreams or unusual behavior as the medicine wears off. Labeling advises reducing verbal, physical and visual stimulation during recovery to limit it. That is why good clinics keep the lights low and the talking to a minimum afterwards.

Reported physical effects across medical use include:

• Rises in blood pressure and heart rate, sometimes sharp
• Slowed or shallow breathing, mainly with overdose or overly fast administration
• Nausea and vomiting
• Dizziness, unsteadiness and poor coordination
• Double vision and involuntary eye movement
• Increased pressure inside the eye or the skull
• Pain or redness at an injection site

At the low doses used for mood or pain, effects are usually milder and shorter, but they fall in the same categories. Dissociation, dizziness, nausea, blurred vision, headache, anxiety and a temporary blood pressure bump are all reported. Judgment and coordination stay impaired after the obvious effects fade, so driving, working and childcare are off the table for the rest of the day. Programs that send medicine home should require a sober adult nearby and a plan for the hours afterwards. If a program does not ask about that, treat it as a warning sign.

Warnings, contraindications and interactions worth flagging

The approved labeling contraindicates use in anyone with known hypersensitivity to the drug. Beyond that, its warnings section centers on monitoring: vital signs and cardiac function during administration, oxygenation and ventilation to guard against respiratory depression, and care during the recovery period. Labeling also warns that pharyngeal and laryngeal reflexes are not suppressed, so the drug alone is not appropriate for procedures involving the airway. Full current labeling for the injection is published on the NIH DailyMed label archive.

Because blood pressure and heart rate can climb, clinicians weigh the drug carefully for anyone in whom a pressure spike would be dangerous. That includes poorly controlled high blood pressure, aneurysms, recent heart events and some vascular disease. Raised pressure inside the eye or skull, a history of psychosis, significant liver disease, active substance use disorder and untreated thyroid overactivity are all part of the screening conversation. Pregnancy and breastfeeding need a direct discussion with a clinician, because human data is limited.

Interaction risk is real and mostly about sedation stacking. Tell the prescriber about everything you take, including items people forget to mention:

• Benzodiazepines, opioids, muscle relaxants, sleep medicines and sedating antihistamines, which can deepen sedation and slow breathing
• Alcohol and cannabis, for the same reason
• Theophylline and aminophylline for asthma, which may lower the seizure threshold
• Thyroid hormone, which can amplify blood pressure and heart rate effects
• Blood pressure medicines, which may need review before dosing
• Stimulants, prescribed or otherwise
• Other psychiatric medicines, including antidepressants and mood stabilizers

Mixing sedatives with this anesthetic outside a monitored setting is where the most serious harm happens. A home dose is not a small dose if you have already taken something that suppresses breathing.

Misuse, dependence and bladder risk with repeated use

Yes, this drug can be misused, and yes, dependence happens. Schedule III status reflects that. Regular non-medical use leads to tolerance, meaning larger amounts to reach the same effect, and to psychological dependence, meaning cravings and difficulty stopping. Withdrawal is not usually life threatening in the way alcohol withdrawal can be, but anxiety, low mood and sleep problems are reported.

The most distinctive long-term harm is urinary. Frequent heavy use has been linked to ketamine-induced ulcerative cystitis: bladder pain, urgency, frequent urination and sometimes blood in the urine. Damage can persist. Memory and thinking problems, plus abdominal pain sometimes called K cramps, also appear in reports from heavy users. General background on dissociative drug misuse is published by the National Institute on Drug Abuse.

Supervised low-dose treatment on a defined schedule is a very different exposure than nightly recreational use. That said, take-home supplies shift responsibility onto the patient, and the FDA has publicly flagged risks with compounded products used at home for psychiatric conditions, including sedation, dissociation and use without monitoring. Its compounding guidance sits on the FDA human drug compounding hub. If a program offers a large take-home quantity with no check-ins, no dose counting and no screening for substance use history, that is a design problem, not a convenience.

Forms, brands and other names you may see

The generic name is ketamine hydrochloride. Ketalar is the injectable brand. Esketamine is sold as Spravato nasal spray. Recreational street names include Special K and K, and the DEA lists several more. Two related molecules appear in research writing: the standard racemic mixture, and arketamine, the R-enantiomer, which is still investigational.

Compounded forms matter most for telehealth. Sublingual troches, lozenges, rapid dissolve tablets and compounded nasal sprays are made by compounding pharmacies to a prescriber’s order. Compounded preparations are not FDA approved and are not reviewed for safety, effectiveness or manufacturing quality before they are sold, even though the active ingredient itself is an approved drug. State-licensed 503A pharmacies compound for individual patients; 503B outsourcing facilities make larger batches under federal oversight. Potency, absorption and stability can differ between pharmacies, so ask which pharmacy fills your prescription and whether it tests finished products.

Those three routes are not interchangeable. Absorption differs, so the same milligram figure does not produce the same exposure. You can compare how programs describe their formats across our Medication Reference Library.

What treatment costs when you pay cash

Most people researching this treatment are paying for it themselves, so the arithmetic deserves plain numbers rather than adjectives. All figures on this site are United States dollars per month, and cash pay is tracked separately from plan or membership fees billed through insurance.

Tracked self-pay monthly figures for at-home programs in our directory: lowest , median , highest . Advertised prices move, so treat any figure as a snapshot rather than a promise.

Clinic infusion pricing is set locally and is not tracked here, so no figure is quoted for it. What drives the total in either setting is the same short list: how many sessions a protocol includes, whether monitoring time involves an anesthesiologist or a nurse, whether the medicine is billed separately from the visit, whether therapy or coaching is bundled, whether labs and cardiac screening cost extra, and whether an introductory package renews at a higher rate. Compounded oral forms usually cost less per session than staffed infusions, because you are not paying for clinical time.

Multiplying a monthly figure into a yearly commitment changes how a program looks, and that maintenance phase is where budgets break.

If you have a plan that might pay part of the bill, run both routes side by side before signing anything.

Insurance realities

Coverage cannot be promised here, and any program that promises it is overselling. Because infusions for depression are off label, plans frequently decline them, and patients often pay cash. Esketamine given in a certified setting is more often billable, but prior authorization is standard and denials happen. Federal parity rules for mental health benefits are explained on the HealthCare.gov mental health coverage page. Call your own plan, ask which billing codes it accepts, ask about the observation charge as well as the drug, and get the answer in writing. Our Sample Savings Report shows how the cost fields are laid out, and the Provider Scoring Method page sets out which dimensions carry weight in a score.

Questions to ask, and when to get urgent help

The quality gap between programs is mostly about screening and follow-up, not about the molecule. Useful questions before you commit:

1. Who prescribes, what are their credentials, and will I speak with them directly?
2. What medical and psychiatric screening happens first, including blood pressure and heart history?
3. Which pharmacy prepares the medicine, and is it compounded or an approved product?
4. How many sessions does the plan assume, and what happens after that?
5. What monitoring is required during and after a dose, and who checks on me?
6. How are symptoms measured between sessions, and what counts as no response?
7. Is talk therapy part of the plan, included or extra?
8. What is the total cash cost for the first month, and what does month three cost?
9. Can I cancel, and are unused sessions refundable?
10. What happens to my other medicines while I am in treatment?

Comparing those answers across programs is easier side by side; our Provider Directory Listings collect the mental health platforms in one place, and free Patient Cost Calculators handle the arithmetic.

Some symptoms need immediate attention rather than a message to a program. Call 911 for chest pain, severe difficulty breathing, seizures, fainting or unresponsiveness. Seek urgent care for confusion or hallucinations that continue well after a session should have ended, a severe headache with a very high blood pressure reading, repeated vomiting, or painful urination and blood in the urine. If suicidal thoughts get worse, call or text 988 for the Suicide and Crisis Lifeline in the United States. Worsening mood during treatment is a reason to stop and speak to a clinician, not a reason to push through another dose.

Authoritative sources

For the primary references behind this page, start with current FDA labeling on DailyMed, then read the clinical review in the NIH StatPearls collection, and check controlled substance status with the DEA drug fact sheet. Labeling and scheduling documents are the authority where any summary and a source disagree.

Educational content, not medical advice. Always consult a qualified clinician before starting, stopping or switching treatment.